Innovative treatment for clinically localized adenocarcinoma of the prostate: The future role of molecular imaging

Prostate

Volumn 41, Issue 3, 1999, Pages 208-212

  D'Amico, Anthony V ^a   Debruyne, Frans ^b   Huland, Hartwig ^c   Richie, Jerome P ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF HAMBURG   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Imaging; Molecular markers; Prostate cancer; Staging

Indexed keywords

BRACHYTHERAPY; COLOR ULTRASOUND FLOWMETRY; CRYOSURGERY; DIAGNOSTIC IMAGING; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIOFREQUENCY;

ADENOCARCINOMA; BRACHYTHERAPY; DIAGNOSTIC IMAGING; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0032756865     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19991101)41:3<208::AID-PROS9>3.0.CO;2-B     Document Type: Note

References (21)

1. D'Amico AV, Whittington R, Broderick GA, Malkowicz SB, Schultz D, Tomaszewski JE, Kaplan I, Beard C, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
2. Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 1998;159:2023-2029.
3. Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke RP, Huland E, Huland H. PSA relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 1999; in press.
4. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, Hamper U, Walsh PC, McNeil BJ. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 1990;323:621-626.
5. D'Amico AV, Whittington R, Tomaszewski JE, Malkowicz SB, Schultz D, Schnall M, Wein A. A critical appraisal of the role of endorectal coil magnetic resonance imaging in the prediction of pathologic stage and postoperative prostate specific antigen failure in patients with clinically organ confined prostate cancer. J Clin Oncol 1996;14:1770-1777.
6. Jager GJ, Ruijter ETG, vd Kaa CA, de la Rosette JJMCH, Oosterhof GON, Thornbury JR, Ruijs SHJ, Barentsz JO. Dynamic turboFLASH subtraction techniques for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997;203:645-652.
7. Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, Vigneron DB. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 1998;206:785-781.
8. Ismail M, Petersen RO, Alexander AA, Newschaffer C, Gomella LG. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease free survival. Urology 1997;50:906-912.
9. Mahmood U, Tung CH, Weissleder R. A novel class of enzyme specific contrast agents for optical imaging of cancer. Proceedings of the 1998 RSNA, 1998, November 27-December 1; Chicago: 1998;321:801A.
10. kip1 gene expression in benign prostatic hyperplasia and prostatic cancer. J Natl Cancer Inst 1998;90:1284-1291.
11. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-165.
12. D'Amico AV, Coleman CN. The role of interstitial radiotherapy in the management of clinically organ confined prostate cancer: the jury is still out. J Clin Oncol 1996;14:304-315.
13. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32: 465-471.
14. D'Amico AV, Cormack R, Tempany CM, Kumar S, Toupless G, Kooy HM, Coleman CN. Real time magnetic resonance image guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1998;42:507-516.
15. Bice WS, Prestidge BR, Grimm PD, Friedland JF, Feygelman V, Roach M III, Prete JJ, Dubois DF, Blasko JC. Centralized multi-institutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;41:921-927.
16. Shinohara K, Connolly JA, Presti JC Jr, Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol 1996;156:115-121.
17. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999;161:156-162.
18. Djavan B, Zlotta AR, Susani M, Heinz G, Shariat S, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology 1997;50:986-993.
19. D'Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant target volume for patients with low risk prostate cancer: does the anteri or base need to be treated? Int J Radiat Oncol Biol Phys 1999;43:587-590.
20. Blasko JC. 1998 annual meeting of the American Brachytherapy Society: "Defining the patient selection process for prostate brachytherapy."
21. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, Von Eschenbash A, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999;161: 304-308.